Medical Developments International (MVP) H1 2025 earnings summary

Executive summary

• Revenue increased 33% year-over-year to $20.0 million for HY25, with net profit after tax of $0.3 million, reversing a $10.9 million loss in the prior period.

• Underlying EBIT improved by $8.0 million to $0.2 million, reflecting stronger volumes, improved pricing, and cost efficiencies.

• Free cashflow improved by $6.8 million year-over-year, with a closing cash balance of $17.6 million.

• Both Pain Management and Respiratory segments delivered strong growth, with Pain Management up 37% and Respiratory up 26%.

• Strategic priorities advanced, including Penthrox volume growth in Australia and Europe, margin improvement, and global expansion.

Financial highlights

• Pain Management revenue rose 37% to $13.1 million, with European revenue up 83% and Australian revenue up 25%.

• Respiratory revenue increased 26% to $6.9 million, with US revenue up 23% and Australian revenue up 25%.

• Underlying EBIT improved by $8.0 million to $0.2 million, with reported EBIT up $13 million due to absence of prior year share-based payment expense.

• Free cashflow improved by $6.8 million, driven by earnings growth, disciplined working capital, and lower capex.

• Group operating costs for the first half of FY25 were approximately $4 million lower than the prior period.

Outlook and guidance

• Full-year underlying EBIT is expected to be strongly improved on FY24, mainly from higher Penthrox prices and operational efficiencies.

• Earnings in the second half of FY25 are expected to be lower than the first half due to phasing and foreign exchange movements.

• Positive operating cashflow is anticipated for the second half of FY25, with full-year CapEx around $2 million.